JPRN-UMIN000018294已完成未知
Feasibility study of a short Trastuzumab infusion in patients with breast cancer. - Feasibility study of a short Trastuzumab infusion in patients with breast cancer.
IPPON MEDICAL SCHOOL MUSASHI KOSUGI HOSPITA0 个研究点目标入组 20 人开始时间: 2015年7月21日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)Systemic administration of corticosteroids 2)At the same time, used other molecular target drugs 3)Patients whose participation in the trial is judged to be inappropriate by the attending doctor
研究者
相似试验
进行中（未招募）
不适用
A pilot study of trastuzumab monotherapy in patients who progressed under a previous platinum-based or 5-fluoropyrimidin-based chemotherapy in metastatic or locally advanced gastric cancerMetastatic or locally advanced gastric cancer (stage IV) with HER2 overexpressionMedDRA version: 7.1Level: PTClassification code 10017767EUCTR2005-001220-37-ATHoffmann-La Roche AG20
招募中
不适用
A phase II clinical study of trastuzumab in combination with capecitabine and cisplatin (XP) in patients with tissue HER2-negative but serum HER2-positive advanced gastric cancerNeoplasmsKCT0004391Asan Medical Center28
已完成
2 期
First-line Trastuzumab monotherapy in patients with HER2-positive metastatic breast cancer(MBC)- a phase 2 studybreast cancerJPRN-C000000263H/D study group on Breast Cancer35
已完成
2 期
Phase II trial of Trastuzumab in combination with Abraxane for patients with HER2-positive metastatic breast cancerHER2-positive Metastatic breast cancerJPRN-UMIN000006159Kumamoto Breast Cancer Cooperative Group23
进行中（未招募）
不适用
A phase III randomized trial of trastuzumab continuation vs discontinuation in combination with 2nd-line chemotherapy after progression on a 1st-line trastuzumab-chemotherapy combination for HER2 overexpressing metastatic breast cancer patients. - THORMetastatic breast cancerMedDRA version: 6.1Level: PTClassification code 10055113EUCTR2006-000703-42-ITROCHE